Impedimed's two blue sky opportunities

Livewire Exclusive

Livewire Markets

After falling as low at 5c per share in 2013, and spending more than two years trading below 50c, renewed interest in Impedimed has recently driven the share price as high as $1.82. So what's caused this astounding rally? Stuart Roberts, Life Sciences Analyst at NDF Research, explains that the change came in 2014 when the company gained the appropriate codes to allow them to be paid by the US healthcare system. "That has unlocked a big market opportunity. About 250,000 women get breast cancer every year, and about 30% of those patients are in danger of getting this condition called lymphedema, so there's a large market opportunity". As well as this, the product has significant potential in the massive cardiac market, and also as a personal health monitoring tool for the private market. In the video below, he discusses Impedimed's current market and these two new blue sky opportunities.

1 stock mentioned

Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.